Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA 1c Levels
JAMA Internal Medicine · 2023
DOI: 10.1001/jamainternmed.2022.6664 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA Internal Medicine, 2023. Verfasst von Elvira D'Andrea und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics; Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Ketoacidosis, Dipeptidyl-Peptidase IV Inhibitors, Heart Failure. Die Arbeit wurde bisher 101-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, FDA HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Importance Sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy has been associated with cardiovascular benefits and a few adverse events; however, whether the comparative effectiveness and safety profiles vary with differences in baseline hemoglobin A 1c (HbA 1c ) levels is unknown.
Objective
To compare cardiovascular effectiveness and safety of treatment with SGLT2i vs dipeptidyl peptidase 4 inhibitor (DPP-4i) in adults with type 2 diabetes (T2D) (1) overall and (2) at varying baseline HbA 1c levels. Design, Setting, and Participants A new-user comparative effectiveness and safety research study was conducted among 144 614 commercially insured adults, initiating treatment with SGLT2i or DPP-4i and with a recorded T2D diagnosis at baseline and at least 1 HbA 1c laboratory result recorded within 3 months before treatment initiation.
Interventions
The intervention consisted of the initiation of treatment with SGLT2i or DPP-4i. Main Outcomes and Measures Primary outcomes were a composite of myocardial infarction, stroke, or all-cause death (modified major adverse cardiovascular events [MACE]) and hospitalization for heart failure (HHF). Safety outcomes were hypovolemia, fractures, falls, genital infections, diabetic ketoacidosis (DKA), acute kidney injury (AKI), and lower-limb amputation. Incidence rate (IR) per 1000 person-years, hazard ratios (HR) and rate differences (RD) with their 95% CIs were estimated controlling for 128 covariates.
Results
A total of 144 614 eligible adults (mean [SD] age, 62 [12.4] years; 54% male participants) with T2D initiating treatment with a SGLT2i (n = 60 523) or a DPP-4i (n = 84 091) were identified; 44 099 had an HbA 1c baseline value of less than 7.5%, 52 986 between 7.5% and 9%, and 47 529 greater than 9%. Overall, 87 274 eligible patients were 1:1 propensity score–matched: 24 052 with HbA 1c less than 7.5%; 32 290 with HbA 1c between 7.5% and 9%; and 30 932 with HbA 1c greater than 9% (to convert percentage of total hemoglobin to proportion of total hemoglobin, multiply by 0.01). The initiation of SGLT2i vs DPP-4i was associated with a reduction in the risk of modified MACE (IR per 1000 person-years 17.13 vs 20.18, respectively; HR, 0.85; 95% CI, 0.75-0.95; RD, −3.02; 95% CI, −5.23 to –0.80) and HHF (IR per 1000 person-years 3.68 vs 8.08, respectively; HR, 0.46; 95% CI, 0.35 to 0.57; RD −4.37; 95% CI, −5.62 to −3.12) over a mean follow-up of 8 months, with no evidence of treatment effect heterogeneity across the HbA 1c levels. Treatment with SGLT2i showed an increased risk of genital infections and DKA and a reduced AKI risk compared with DPP-4i. Findings were consistent by HbA 1c levels, except for a more pronounced risk of genital infections associated with SGLT2i for HbA 1c levels of 7.5% to 9% (IR per 1000 person-years 68.5 vs 22.8, respectively; HR, 3.10; 95% CI, 2.68-3.58; RD, 46.22; 95% CI, 40.54-51.90). Conclusions and Relevance In this comparative effectiveness and safety research study among adults with T2D, SGLT2i vs DPP-4i treatment initiators had a reduced risk of modified MACE and HHF, an increased risk of genital infections and DKA, and a lower risk of AKI, regardless of baseline HbA 1c .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Pharmacoeconomics; Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
- Diabetes Center, Massachusetts General Hospital, Harvard Medical School, Boston.
- Division of Kidney Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
- New England Geriatric Research Education and Clinical Center, VA Boston Healthcare System, Boston, Massachusetts.
Förderung
- NIA NIH HHS
- FDA HHS
Zitieren
APA
D'Andrea, E., Wexler, D. J., Kim, S. C., Paik, J. M., Alt, E., & Patorno, E. (2023). Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA 1c Levels. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2022.6664
Vancouver
D'Andrea E, Wexler DJ, Kim SC, Paik JM, Alt E, Patorno E. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA 1c Levels. JAMA Internal Medicine. 2023. doi:10.1001/jamainternmed.2022.6664
BibTeX
@article{DAndrea2023,
author = {D'Andrea, Elvira and Wexler, Deborah J and Kim, Seoyoung C and Paik, Julie M and Alt, Ethan and Patorno, Elisabetta},
title = {Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA 1c Levels},
journal = {JAMA Internal Medicine},
year = {2023},
doi = {10.1001/jamainternmed.2022.6664}
}
EUVIMED